Sanmeet Deo

It's like, you know, there's something that the FDA is going to be able to wrap their head around a little easier for this particular medicine.

And then also thinking about a lot of these kind of interventional tools, it's like, where's the service happening?

There's going to be a little, a bit of a service, you know, kind of flourishing happening in pockets.

So that is an investment.

You know, if you, if you can get into the places that really proliferate this in the beginning, some of the healthcare systems and things that can go well too.

a lot of the money to be made might be there where the service actually costs the money.

The real revenue is the $10,000, $20,000 treatment versus the five or $800 drug.

So that's something to consider.

I don't think they're that yet interested in it, quite frankly.

And the reason is, again, because it's this interventional model, it's typically used for treatment resistance when drugs are failing.

So I think they still have, you know, the lion's share of patients out there that are going to use drugs.

antidepressants and other medications and sometimes they need them.

I don't honestly think this will impact that industry all that much, at least for a long time is my guess.

I think they're not that interested yet in it, but I would say, let's see what happens in 10, 15 years if we get a number of approvals.

And there is a subset of people that are like, I won't do those medications.

I want something to help me get to the bottom of what I'm really dealing with.

And I want to go down that road.

And it, you know, a subset enough of those people do that.

And maybe we will start to see them get more interested.

But I haven't really seen that as, they're not on the offensive so much.